Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement in muscle function with ...
1d
Clinical Trials Arena on MSNAmgen’s gMG therapy cuts disease symptoms at one-year markAmgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of gMG patients after 52 weeks in a Phase III ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
NEW YORK, Feb. 18, 2025 /PRNewswire/ -- A newly identified part of a brain circuit mixes sensory information, memories, and emotions to tell whether things are familiar or new, and important or ...
After hours: March 13 at 7:59:56 PM EDT Loading Chart for ACHR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results